ARDS - Aridis Pharmaceuticals Inc Stock Price, Fair Value and News

0USD0Market Closed

ARDS Alerts

2 major insider buys recently.

ARDS Stock Price

View Fullscreen

ARDS RSI Chart

ARDS Valuation

Market Cap

3.1M

Price/Earnings (Trailing)

-2.73

Price/Sales (Trailing)

0.14

Price/Free Cashflow

-0.17

ARDS Price/Sales (Trailing)

ARDS Profitability

Free Cashflow Yield

-573.2%

ARDS Fundamentals

ARDS Revenue

ARDS Earnings

Breaking Down ARDS Revenue

Last 7 days

-100%

Last 30 days

-100%

Last 90 days

-100%

Trailing 12 Months

-82.9%

How does ARDS drawdown profile look like?

ARDS Financial Health

ARDS Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	3.0M	21.4M	21.5M	0
2022	4.4M	4.6M	1.9M	0
2021	0	2.0M	3.1M	4.1M
2020	0	1.0M	1.0M	1.0M
2019	3.5M	3.4M	2.4M	1.0M
2018	1.3M	1.8M	2.3M	2.8M
2017	0	0	0	860.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Aridis Pharmaceuticals Inc

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.

CEO	Dr. Vu L. Truong Ph.D.
WEBSITE	aridispharma.com
INDUSTRY	Biotechnology
EMPLOYEES	37

Aridis Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Aridis Pharmaceuticals Inc? What does ARDS stand for in stocks?

ARDS is the stock ticker symbol of Aridis Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aridis Pharmaceuticals Inc (ARDS)?

As of Mon Jul 22 2024, market cap of Aridis Pharmaceuticals Inc is 3.12 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARDS stock?

You can check ARDS's fair value in chart for subscribers.

Is Aridis Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ARDS is over valued or under valued. Whether Aridis Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Aridis Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARDS.

What is Aridis Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Jul 22 2024, ARDS's PE ratio (Price to Earnings) is -2.73 and Price to Sales (PS) ratio is 0.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARDS PE ratio will change depending on the future growth rate expectations of investors.